<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Continuous glucose monitor (CGM)</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Abbott misses Q4 expectations</title>
      <description>
        <![CDATA[Abbott Laboratories reported fourth quarter sales below expectations before the market opened on Jan. 22, sending the stock down nearly 12% from the prior day's closing. The biggest hits came from contraction in the nutrition group along with continued disruption in the diagnostics unit from volume-based procurement in China. Medical devices suffered from market share loss in electrophysiology and slower than expected uptake of continuous glucose monitors. The pharma group performed as anticipated, posting 7% growth.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728077</guid>
      <pubDate>Thu, 22 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728077-abbott-misses-q4-expectations</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-21-Abbott-sign.webp?t=1603296108" type="image/png" medium="image" fileSize="579854">
        <media:title type="plain">Abbott sign</media:title>
        <media:description type="plain">Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>​Positive changes ahead for diabetes in 2026</title>
      <description>
        <![CDATA[Over the last year, diabetes technology saw significant changes, including the acceleration of patch pumps, ever-smaller continuous glucose monitors (CGM), implanted CGMs and increased interest in devices that measure additional chemicals in blood without needles.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727565</guid>
      <pubDate>Mon, 05 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727565-positive-changes-ahead-for-diabetes-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/human-body-metabolism.webp?t=1726239536" type="image/jpeg" medium="image" fileSize="320060">
        <media:title type="plain">Art concept for metabolism</media:title>
      </media:content>
    </item>
    <item>
      <title>Medicare’s competitive bidding program draws opposition</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services has posted the home health final rule for calendar year 2026 and has established a framework for competitive bidding for products such as continuous glucose monitors, a move that is struggling to find support among stakeholders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726445</guid>
      <pubDate>Tue, 02 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726445-medicares-competitive-bidding-program-draws-opposition</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>OIG sees potential for savings in Medicare CGM coverage</title>
      <description>
        <![CDATA[The Office of Inspector General issued a report stating that the Medicare program could save “tens of millions of dollars” in a single year on continuous glucose monitors and associated supplies if the Centers for Medicare & Medicaid Services acted to apply price pressure on suppliers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726404</guid>
      <pubDate>Wed, 26 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726404-oig-sees-potential-for-savings-in-medicare-cgm-coverage</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Dexcom Smart Basal for insulin optimization</title>
      <description>
        <![CDATA[Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, Smart Basal uses data from Dexcom’s G7 15 Day sensor with doses logged by the user to personalize recommendations and adjust long-acting insulin doses, with direction from the patient’s health care provider.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726211</guid>
      <pubDate>Wed, 19 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726211-fda-clears-dexcom-smart-basal-for-insulin-optimization</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Halloween turns scary for Dexcom despite strong Q3</title>
      <description>
        <![CDATA[Dexcom Inc. executives may have thought a $30 million beat of the consensus estimates for third quarter revenue and 20% year-over-year organic growth provided a treat to shareholders, but investors seemed to feel tricked instead. The continuous glucose monitoring powerhouse saw its share price drop a frightening 17% in the first two hours of trading on Oct. 31, pushing it down by one-third from its peak of $89.53 in late July. Investors appear to have been spooked by the company’s conservative projections for 2026, following issues with its G7 sensor, which management said have been largely resolved.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725473</guid>
      <pubDate>Fri, 31 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725473-halloween-turns-scary-for-dexcom-despite-strong-q3</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Dexcom faces class action lawsuit following FDA warning</title>
      <description>
        <![CDATA[San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a mere seven months and a recall announced in July, suggesting that litigation often follows other sources of bad news for firms in the med-tech business.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725144</guid>
      <pubDate>Tue, 21 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725144-dexcom-faces-class-action-lawsuit-following-fda-warning</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/US-flag-gavel-book.webp?t=1719870359" type="image/jpeg" medium="image" fileSize="164532">
        <media:title type="plain">US flag, gavel, book</media:title>
      </media:content>
    </item>
    <item>
      <title>Roche gets CE mark for CGM, Mysugr integration</title>
      <description>
        <![CDATA[Roche Holdings AG received CE mark approval for the integration of its AI-enabled continuous glucose monitoring system, Accu-Chek Smartguide, with the Mysugr diabetes management app. The integrated solution, which combines predictive CGM technology with therapy data in one place, will simplify the daily decision-making for users managing their diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724112</guid>
      <pubDate>Wed, 17 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724112-roche-gets-ce-mark-for-cgm-mysugr-integration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Roche-Accu-Chek-17sept25.webp?t=1758138643" type="image/jpeg" medium="image" fileSize="128084">
        <media:title type="plain">Roche Accu-Chek</media:title>
        <media:description type="plain">Roche Accu-Chek Smartguide. Credit: Roche</media:description>
      </media:content>
    </item>
    <item>
      <title>Senseonics reclaims Eversense 365 distribution from Ascensia</title>
      <description>
        <![CDATA[After a five-year partnership, Senseonics Holdings Inc. and Ascensia Diabetes Care Holdings AG, a unit of Tokyo-based PHC Holdings Corp., agreed to transition worldwide commercialization and distribution of Senseonics’ Eversense 365 implantable continuous glucose monitor back to Senseonics beginning on Jan. 1, 2026. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/724110</guid>
      <pubDate>Wed, 17 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724110-senseonics-reclaims-eversense-365-distribution-from-ascensia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Eversense-365-17sept24.webp?t=1726609965" type="image/jpeg" medium="image" fileSize="145293">
        <media:title type="plain">Eversense 365</media:title>
        <media:description type="plain">Senseonic Holdings Inc. Eversense 365. Credit: Senseonic Holdings</media:description>
      </media:content>
    </item>
    <item>
      <title>Signos adds AI to CGM to drive weight loss</title>
      <description>
        <![CDATA[Signos Inc. landed U.S. FDA clearance for its over-the-counter glucose monitoring system, which combines Dexcom Inc.'s non-prescription Stelo continuous glucose monitor with an AI-powered platform focused on weight management and metabolism. The sensor transmits glucose readings to a smartphone app that interprets the data, provides guidance for healthy habits and educates the user. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723195</guid>
      <pubDate>Thu, 21 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723195-signos-adds-ai-to-cgm-to-drive-weight-loss</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/stelo-21aug25.webp?t=1755813087" type="image/jpeg" medium="image" fileSize="5328">
        <media:title type="plain">Signots Stelo</media:title>
        <media:description type="plain">Signos Stelo CGM. Credit: Courtesy Signos Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sava raises $19M for multi-molecule biosensor</title>
      <description>
        <![CDATA[Sava Technologies Ltd. raised $19 million in a series A funding round for its multi-molecule biosensor platform that can detect biomarkers just beneath the skin, in real-time. The funds will go towards its first product, a continuous glucose monitor, which early clinical data showed can generate accurate glucose readings for up to 10 days of continuous wear.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722570</guid>
      <pubDate>Fri, 01 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722570-sava-raises-19m-for-multi-molecule-biosensor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/sava-biosensor-1aug25.webp?t=1754084887" type="image/jpeg" medium="image" fileSize="209391">
        <media:title type="plain">Sava Biosensor</media:title>
        <media:description type="plain">Sava multi-molecule biosensor. Credit: courtesy Sava Technologies</media:description>
      </media:content>
    </item>
    <item>
      <title>Trinity unveils AI-powered CGM+ biosensor</title>
      <description>
        <![CDATA[Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body temperature at the same time. The company believes that as precision medicine becomes central to health care, especially with the collection of real-time data, CGM+ will become a critical enabler of AI-based diagnostics, behavioral coaching and chronic disease management.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722533</guid>
      <pubDate>Mon, 28 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722533-trinity-unveils-ai-powered-cgm-biosensor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/trinity-cgm28july25-2.webp?t=1753740170" type="image/jpeg" medium="image" fileSize="149569">
        <media:title type="plain">Trinity CGM+</media:title>
        <media:description type="plain">Trinity CGM+. Credit: Trinity Biotech</media:description>
      </media:content>
    </item>
    <item>
      <title>Glucomodicum reports positive data from its needle-free CGM</title>
      <description>
        <![CDATA[Glucomodicum Oy reported positive results from a clinical study in which its needle-free continuous glucose monitor, Talisman, was tested in participants across both standard multi-hour glucose tolerance and ambulatory conditions involving exercise and meals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721796</guid>
      <pubDate>Tue, 08 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721796-glucomodicum-reports-positive-data-from-its-needle-free-cgm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Glucomodicum-CGM-8july25.webp?t=1752008588" type="image/jpeg" medium="image" fileSize="260202">
        <media:title type="plain">Glucomodicum-CGM-8july25.jpg</media:title>
        <media:description type="plain">Glucomodicum Talisman. Credit: Glucomodicum</media:description>
      </media:content>
    </item>
    <item>
      <title>CMS eyes competitive bidding for CGMs, insulin pumps</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous glucose monitors and insulin pumps to competitive bidding, but the agency is also considering a more rapid pace of replacement of these technologies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721618</guid>
      <pubDate>Tue, 01 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721618-cms-eyes-competitive-bidding-for-cgms-insulin-pumps</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/thumb/CMS-logo-and-website.webp?t=1689968783" type="image/jpeg" medium="image" fileSize="62055">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>Pump manufacturers: Patches are the fix for low AID uptake</title>
      <description>
        <![CDATA[The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with clear health benefits and payer coverage, why has pump adoption been so slow? Insulet Corp.’s Omnipod 5’s rapid rise to dominance demonstrated unequivocally that people with diabetes want a stick-and-forget device. The American Diabetes Association’s 85th Scientific Sessions in Chicago on June 20-23 made just as clear that pump makers received the message with several companies outlining plans to introduce a patch system in the next two years. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721239</guid>
      <pubDate>Thu, 26 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721239-pump-manufacturers-patches-are-the-fix-for-low-aid-uptake</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/insulet-dexcom-20june24.webp?t=1750973216" type="image/jpeg" medium="image" fileSize="93363">
        <media:title type="plain">insulet dexcom CGM</media:title>
        <media:description type="plain">Insulet’s Omnipod 5 with Dexcom G6 connectivity. Credit: Insulet Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Multiple multianalyte sensors for diabetes on horizon</title>
      <description>
        <![CDATA[Abbott Laboratories grabbed attention in early June with its announcement of a partnership with Tandem Diabetes Care Inc. to develop a multianalyte sensor for people with diabetes that would measure ketones as well as glucose.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721229</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721229-multiple-multianalyte-sensors-for-diabetes-on-horizon</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-21-Abbott-sign.webp?t=1603296108" type="image/png" medium="image" fileSize="579854">
        <media:title type="plain">Abbott sign</media:title>
        <media:description type="plain">Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>In-patient BYOD still troublesome for CGM makers</title>
      <description>
        <![CDATA[With a growing number of people wearing continuous glucose monitors and an ever-shrinking number of hospital-based nurses, bringing your own device or using personal CGMs to measure glucose levels during hospitalizations seems like a no-brainer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721227</guid>
      <pubDate>Wed, 25 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721227-in-patient-byod-still-troublesome-for-cgm-makers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Dexcom-G6-11-11.webp?t=1600984902" type="image/png" medium="image" fileSize="640671">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">G6 CGM system. Credit: Dexcom Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Diabetes partnerships abound ahead of ADA</title>
      <description>
        <![CDATA[With the American Diabetes Association annual meeting a week away, four major diabetes tech companies queued up new partnerships for their devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720763</guid>
      <pubDate>Tue, 10 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720763-diabetes-partnerships-abound-ahead-of-ada</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Kakao Healthcare brings CGM app to Japan</title>
      <description>
        <![CDATA[Step aside, Marco Polo: <a href="https://www.bioworld.com/keywords/45862-kakao-healthcare-corp">Kakao Healthcare Corp.</a> plans to bring PASTA to Japan. PASTA is Kakao's AI-based continuous glucose monitoring (CGM) management mobile application, which will be available in Japan through a new subsidiary as the health care company works to expand its global presence. &nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/719946</guid>
      <pubDate>Fri, 16 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719946-kakao-healthcare-brings-cgm-app-to-japan</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Kakao_Pasta-01feb24.webp?t=1706827230" type="image/jpeg" medium="image" fileSize="179361">
        <media:title type="plain">Kakao Pasta app</media:title>
        <media:description type="plain">Kakao Healthcare Corp. PASTA mobile app for glucose monitoring. Credit: Kakao Healthcare</media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott studies show CGM users have fewer hospitalizations</title>
      <description>
        <![CDATA[A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces hospitalizations in people with type 1 diabetes and in those with type 2 diabetes who use insulin compared to use of capillary blood glucose monitoring. Abbott Laboratories’s REFLECT real-world studies showed that use of its Freestyle Libre CGMs reduced the severity of cardiovascular conditions associated with diabetes and, consequently, led to fewer in-patient stays.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719937</guid>
      <pubDate>Thu, 15 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719937-abbott-studies-show-cgm-users-have-fewer-hospitalizations</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-31-Abbott-FreeStyle-Libre-3-Sensor-Smartphone.webp?t=1654033980" type="image/png" medium="image" fileSize="128913">
        <media:title type="plain">Freestyle Libre 3 sensor with smartphone app</media:title>
        <media:description type="plain">Abbott’s Freestyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings directly to smartphones for people with diabetes.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Diabetes segment reports good news all around</title>
      <description>
        <![CDATA[Senseonics Holdings Inc. and Sequel Med Tech LLC revealed plans to develop an automated insulin delivery system using the Eversense one-year, implantable continuous glucose monitoring system to increase flexibility for people with type 1 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719642</guid>
      <pubDate>Wed, 07 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719642-diabetes-segment-reports-good-news-all-around</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Merger-puzzle-pieces-arrow-hands.webp?t=1644441920" type="image/png" medium="image" fileSize="99873">
        <media:title type="plain">Hands holding arrow-shaped puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic continues to close gap in diabetes tech</title>
      <description>
        <![CDATA[Medtronic plc’s diabetes unit posted another win with the U.S. FDA approval of the Simplera continuous glucose monitoring sensor for use with the Minimed 780G pump system, helping the company catch up with competitors Abbott Laboratories and Dexcom Inc. Medtronic plans to begin a limited launch of the Simplera Sync in the U.S. this fall.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719386</guid>
      <pubDate>Mon, 21 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719386-medtronic-continues-to-close-gap-in-diabetes-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Medtronic_plc_MiniMed_780G_system_Simplera_Sync_sensor-21apr25.webp?t=1745272478" type="image/jpeg" medium="image" fileSize="146638">
        <media:title type="plain">Medtronic Simplera Sync and Minimed 780G pump system</media:title>
        <media:description type="plain">Medtronic Simplera Sync and Minimed 780G pump system. Credit: Medtronic</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Dexcom G7 15 Day</title>
      <description>
        <![CDATA[The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with diabetes. The company said it now takes the lead with the 15-day duration, but Abbott Laboratories also offers 15 days of useful life for its Freestyle Libre 3 plus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718915</guid>
      <pubDate>Fri, 11 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718915-fda-clears-dexcom-g7-15-day</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA says changes in Dexcom G6, G7 sensors constitute misbranding</title>
      <description>
        <![CDATA[The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen content in glucose test dishes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718261</guid>
      <pubDate>Wed, 26 Mar 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718261-fda-says-changes-in-dexcom-g6-g7-sensors-constitute-misbranding</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Insulet glows with RADIANT results, CGMs becoming T2D standard</title>
      <description>
        <![CDATA[For people with type 1 or type 2 diabetes and the companies developing technologies to help them, the International Conference on Advanced Technologies & Treatments for Diabetes delivered an abundance of good news. On the type 1 diabetes front, Insulet Corp.’s RADIANT study demonstrated massive improvement in time in range as well as lower glycemic levels for patients switching from multiple injections to the Omnipod 5 automated insulin delivery system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718211</guid>
      <pubDate>Tue, 25 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718211-insulet-glows-with-radiant-results-cgms-becoming-t2d-standard</link>
      <media:content url="https://www.bioworld.com/ext/resources/2023/05/08/OP5_INSU_POD_PDM_NoADH_RIGHT_RGB_With_Disclaimer.webp?t=1724789780" type="image/jpeg" medium="image" fileSize="69380">
        <media:title type="plain">OP5_INSU_POD_PDM_NoADH_RIGHT_RGB.jpg</media:title>
        <media:description type="plain">The Insulet Omnipod 5 AID.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tandem’s Control-IQ+ looks like a smart move for insulin-using T2D</title>
      <description>
        <![CDATA[Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 at the 18th International Conference on Advanced Technologies & Treatments for Diabetes and published in <em>The New England Journal of Medicine</em> demonstrated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717983</guid>
      <pubDate>Wed, 19 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717983-tandems-control-iq-looks-like-a-smart-move-for-insulin-using-t2d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Control-IQ-3-18.webp?t=1742421896" type="image/jpeg" medium="image" fileSize="118655">
        <media:title type="plain">Control-IQ+ by Tandem Diabetes Care Inc.</media:title>
        <media:description type="plain">Control-IQ+. Credit: Tandem Diabetes Care Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tandem wins FDA clearance for automated insulin delivery system</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Tandem Diabetes Care Inc. reported that its next-generation automated insulin delivery algorithm, Control-IQ+ technology (Control-IQ+), is cleared by the U.S. FDA for use by people with type 2 diabetes (T2D) ages 18 and older.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717619</guid>
      <pubDate>Thu, 27 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717619-tandem-wins-fda-clearance-for-automated-insulin-delivery-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Tandem-27feb25.webp?t=1740700370" type="image/jpeg" medium="image" fileSize="157523">
        <media:title type="plain">Tandem</media:title>
        <media:description type="plain">The t:slim X2 insulin pump with Control-IQ+ technology from Tandem Diabetes Care.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Senseonic’s Eversense one-year implantable CGM </title>
      <description>
        <![CDATA[The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable sensors such as those offered by Abbott Laboratories and Dexcom Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712616</guid>
      <pubDate>Tue, 17 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712616-fda-clears-senseonics-eversense-one-year-implantable-cgm</link>
    </item>
    <item>
      <title>FDA clears Senseonic’s Eversense one-year implantable CGM</title>
      <description>
        <![CDATA[The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable sensors such as those offered by Abbott Laboratories and Dexcom Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712248</guid>
      <pubDate>Tue, 17 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712248-fda-clears-senseonics-eversense-one-year-implantable-cgm</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Eversense-365-17sept24.webp?t=1726609965" type="image/jpeg" medium="image" fileSize="145293">
        <media:title type="plain">Eversense 365</media:title>
        <media:description type="plain">Senseonic Holdings Inc. Eversense 365. Credit: Senseonic Holdings</media:description>
      </media:content>
    </item>
    <item>
      <title>Dexcom data: CGM for type 2 diabetes without insulin treatment</title>
      <description>
        <![CDATA[Dexcom Inc. revealed data from several studies showing significant benefits of its continuous glucose monitoring technology on adults with type 2 diabetes who are not treated with insulin. In one study, 100% of these users made dietary changes after starting to use Dexcom CGM, with 91% feeling empowered to manage their condition and 27% improving medication adherence after six months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712046</guid>
      <pubDate>Thu, 12 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712046-dexcom-data-cgm-for-type-2-diabetes-without-insulin-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
